PARP1 and neoplasm: With the help of next-generation sequencing, the development of biomedical technologies and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells, such as homologous recombination deficiencies, enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors.